European Journal of Cancer最新文献

{"title":"Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg.","authors":"Julian Kött, Tim Zell, Noah Zimmermann, Alessandra Rünger, Daniel J Smit, Finn Abeck, Glenn Geidel, Inga Hansen-Abeck, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Carola Berking, Ralf Gutzmer, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone, Imke von Wasielewski, Peter Mohr, Friedegund Meier, Sebastian Haferkamp, Konstantin Drexler, Rudolf Herbst, Ivonne Kellner, Jochen Utikal, Sebastian A Wohlfeil, Claudia Pföhler, Leonie Adam, Patrick Terheyden, Jens Ulrich, Frank Meiss, Monica Möbes, Julia Welzel, Bastian Schilling, Fabian Ziller, Martin Kaatz, Alexander Kreuter, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Carsten Weishaupt, Svea Hüning, Lucie Heinzerling, Carmen Loquai, Gaston Schley, Thilo Gambichler, Harald Löffler, Stephan Grabbe, Erwin Schultz, Nina Devereux, Jesscia C Hassel, Jan-Ch Simon, Ulrike Raap, Chalid Assaf, Claus-Detlev Klemke, Cord Sunderkötter, Silke C Hofmann, Saskia Wenk, Michael Tronnier, Silke Thies, Markus V Heppt, Alexander Eggermont, Hans-Joachim Schulze, Christos C Zouboulis, Thomas Tüting, Alexander T Bauer, Stefan W Schneider, Christoffer Gebhardt","doi":"10.1016/j.ejca.2024.115159","DOIUrl":"10.1016/j.ejca.2024.115159","url":null,"abstract":"<p><strong>Background: </strong>Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through the modulation of coagulation and platelet activity. Both have been found to play an important role in the tumor microenvironment, tumor growth and metastasis. Preclinical studies indicate a beneficial effect, clinical data has been inconsistent.</p><p><strong>Methods: </strong>We examined a cohort of advanced, non-resectable melanoma patients (n = 2419) derived from the German prospective multicenter skin cancer registry ADOReg, who were treated with immune checkpoint inhibitors (ICI). The patients were classified based on whether it was documented that they received platelet aggregation inhibition (PAI) (n = 137) (acetylsalicylic acid (ASA) or clopidogrel), anticoagulation (AC) (n = 185) (direct oral anticoagulation (DOAC), phenprocoumon, heparins) at the start of ICI or no antithrombotic medication (n = 2097) at any point during ICI treatment. The study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>A significantly improved PFS was observed in patients documented to receive ASA (15.1 vs 6.4 months, HR 0.67, 95 % CI: 0.5 to 0.88, p = 0.0047) as well as in patients to receive AC (15.1 vs. 6.4 months, HR 0.7, 95 % CI: 0.53 to 0.91, p = 0.01) compared to patients for whom no antithrombotic medication was documented. Multivariate analysis of OS showed significant risk reduction in patients who received DOAC (HR 0.68, 95 % CI: 0.49 to 0.92, p = 0.0170) or phenprocoumon (HR: 0.44, 95 % CI: 0.19 to 0.85, p = 0.0301).</p><p><strong>Conclusion: </strong>Our study indicates a positive prognostic effect of anticoagulant and antiplatelet concomitant medication in melanoma patients receiving ICI. Further studies are needed to confrim the cancer-related benefit of adding anticoagulation or platelet inhibition to ICI treatment.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"115159"},"PeriodicalIF":7.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): A population-based study.","authors":"Annalisa Trama, Alice Bernasconi, Adela Cañete, Marià Carulla, Laetitia Daubisse-Marliac, Silvia Rossi, Roberta De Angelis, Arantza Sanvisens, Alexander Katalinic, Keiu Paapsi, Philip Went, Mohsen Mousavi, Marcel Blum, Andrea Eberle, Sébastien Lamy, Riccardo Capocaccia, Fabio Didonè, Laura Botta","doi":"10.1016/j.ejca.2024.115147","DOIUrl":"10.1016/j.ejca.2024.115147","url":null,"abstract":"<p><strong>Background: </strong>Rare cancers correspond to approximately 200 clinical entities, which can be grouped into 12 families. Updated data are available for childhood and haematological cancers, ie, for only two of the 12 families of rare cancer. We provide incidence and survival for the remaining ten families of rare adult solid cancers (RAC), across 29 EU Member States and over time. We also evaluate the association between resources invested in health and survival from RACs.</p><p><strong>Methods: </strong>We used the EUROCARE-6 database, which includes data from 108 cancer registries from 29 countries. We calculated incidence rates (IR) and 5-year relative survival (RS) for cases diagnosed during 2006-2013. We calculated 5-year RS in the follow-up period 2010-2014 using the period approach (last follow-up: December 31, 2014). We estimated changes in 5-year RS and IR over the period 2000-2013. We used a forest plot to report the differences in RS among countries with the highest and lowest health spending.</p><p><strong>Results: </strong>RACs are heterogeneous in terms of incidence, survival, sex, and age distribution. Several RACs (eg, those of the hypopharynx, small intestine, and trachea) still have a 5-year RS < 30 %, which is not improving. Survival differs among European countries and is higher in countries with the greatest investments in health. The incidence of smoking-related RACs is decreasing but rising in HPV-related RACs.</p><p><strong>Conclusion: </strong>Investments in health and healthcare networks at national and European level can help increase the survival of RACs, especially those requiring centralisation of care (eg, bone sarcomas, penile cancer). These investments are critical considering that survival from RACs is not significantly improving. Our results unmask the heterogeneity of RACs, which needs to be considered in clinical trial design. Finally, our findings support the importance of prevention strategies for known risk factors such as smoking.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"115147"},"PeriodicalIF":7.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial.","authors":"Kaiyang Ding, Hailing Liu, Lixia Sheng, Jie Ma, Xiaohui Zhang, Hongming Huang, Wei Shi, Hongling Peng, Lei Cao, Wei Wu, Jianyong Li, Lei Fan","doi":"10.1016/j.ejca.2024.115155","DOIUrl":"10.1016/j.ejca.2024.115155","url":null,"abstract":"<p><strong>Background: </strong>Extranodal natural killer/T-cell lymphoma (ENKTCL) is almost always fatal after the failure of asparaginase. This phase II study aimed to investigate the efficacy and safety of tislelizumab combined with gemcitabine and oxaliplatin (Tisle-GemOx) in patients with ENKTCL failing asparaginase.</p><p><strong>Methods: </strong>Eligible patients received Tisle-GemOx as initial induction for 6-8 cycles at 21-day intervals. Responders continued tislelizumab maintenance every two months for two years. The primary endpoint was the best complete response rate (CRR).</p><p><strong>Results: </strong>As of September 2023, 32 patients were enrolled in our study. Among the 30 efficacy-evaluable patients, the best CRR was 60 %, meeting the primary efficacy endpoint. With a median follow-up of 22.6 months, the median progression-free survival (PFS) was 7.4 months and the 1-year PFS rate was 46.4 %. Subgroup analyses showed that shorter PFS was associated with previous lines of chemotherapy ≥ 2 (P = 0.034) and concomitant hemophagocytic lymphohistiocytosis (P = 0.040). Pseudo-progression was observed in three patients (10 %). The most common grade ≥ 3 toxicities were lymphopenia (25 %) and anemia (15.6 %).</p><p><strong>Conclusions: </strong>Tisle-GemOx exhibits promising anti-tumor activity and manageable toxicities as a salvage therapy for ENKTCL failing asparaginase. Further long-term follow-up is necessary to evaluate the durability of the response with tislelizumab maintenance in this patient population.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"115155"},"PeriodicalIF":7.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.","authors":"Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, Phil F Cheng, Isaac F Hughes, Ester Simeone, Kamaneh Montazeri, Piyush Grover, Inderjit Mehmi, Camille L Gerard, Caroline Gaudy-Marqueste, Jean-Jacques Grob, Olivier Michielin, Omid Hamid, Georgina V Long, Ryan Sullivan, Ellen Kapiteijn, Douglas B Johnson, Paolo A Ascierto, Anthony M Joshua, Richard D Carvajal, Marcus O Butler, Jessica C Hassel, Reinhard Dummer","doi":"10.1016/j.ejca.2024.115161","DOIUrl":"10.1016/j.ejca.2024.115161","url":null,"abstract":"<p><strong>Background: </strong>Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to investigate the efficacy and safety of the sequence of tebentafusp and ICIs.</p><p><strong>Methods: </strong>Patients with HLA-A * 02:01 positive mUM, or metastatic GNA11/GNAQ mutant melanocytic tumors treated with tebentafusp followed by ICIs (group 1) or the inverse sequence (group 2) at any treatment line were retrospectively identified. The primary objective was OS rate at 2 years.</p><p><strong>Results: </strong>131 patients were included; 51 in group 1 and 80 in group 2. 30 % in group 1 % and 40 % in group 2 had normal baseline lactate dehydrogenase (LDH, p = 0.05). 94 % in group 1 % and 77 % in group 2 had multilobular liver disease (p = 0.02). Median OS was 22.4 months (95 % CI 19-24.8) in group 1 and 33.6 months (95 % CI 28.9-43) in group 2 (p = 0.004). Total median PFS was 12 months (95 % CI 10.7-18.8) in group 1 and 20.3 months (95 % CI 17.2-27.3) in group 2 (p = 0.04). The frequency of cytokine release syndrome was higher in group 2 (15 % vs 27 %). Other clinical factors were associated with short total PFS in the multivariable analysis.</p><p><strong>Conclusions: </strong>Both treatment sequences are clinically feasible. A clinical benefit was noted in the sequential combination of ICIs followed by tebentafusp. This observation is limited by the retrospective nature of the study and merits further investigation in prospective clinical trials.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"115161"},"PeriodicalIF":7.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defying the odds: Outstanding survival in lung-only pancreatic cancer treated by Trifluridine-Tipiracil.","authors":"K Sarti, V Boige, G M Camilleri, M Ducreux, A Boilève","doi":"10.1016/j.ejca.2024.115125","DOIUrl":"10.1016/j.ejca.2024.115125","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":" ","pages":"115125"},"PeriodicalIF":7.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.","authors":"De-Shen Wang, William Pat Fong, Lei Wen, Yan-Yu Cai, Chao Ren, Xiao-Jun Wu, Tian-Qi Zhang, Fei Cao, Meng-Xuan Zuo, Bin-Kui Li, Yun Zheng, Li-Ren Li, Gong Chen, Pei-Rong Ding, Zhen-Hai Lu, Rong-Xin Zhang, Yun-Fei Yuan, Zhi-Zhong Pan, Yu-Hong Li","doi":"10.1016/j.ejca.2024.115154","DOIUrl":"10.1016/j.ejca.2024.115154","url":null,"abstract":"<p><strong>Background: </strong>Hepatic artery infusion (HAI) chemotherapy, particularly with floxuridine (FUDR), has previously shown effectiveness in improving recurrence-free survival (RFS) in colorectal cancer (CRC) patients with colorectal liver metastases (CRLM). Nonetheless, its adjuvant use alongside modern systemic chemotherapy remains unevaluated.</p><p><strong>Patients and methods: </strong>The HARVEST trial is an open-label, randomized, controlled study conducted from May 2018 to August 2021. CRC patients with resectable primary tumors and CRLM were recruited and randomized to receive standard systemic chemotherapy only (non-HAI group) or in combination with HAI-FUDR (HAI group). However, due to a FUDR manufacturing shortage, the study was terminated early after enrolling 92 patients. The primary endpoint was the 3-year RFS rate, with secondary endpoints including overall survival (OS), liver-specific RFS, and adverse events.</p><p><strong>Results: </strong>Of the 92 randomized patients, 77 were included in the modified intention-to-treat analysis. Three-year RFS rates were comparable between the HAI (N = 38) and non-HAI (N = 39) groups (31.4 % vs. 34.4 %; P = 0.28). However, improved 1-year RFS and a longer expected five-year OS were observed in the HAI group. While exploratory subgroup analysis suggested potential RFS benefits for patients with multiple liver metastases, RAS/BRAF mutations, and positive postoperative ctDNA methylation, multivariable analysis did not identify these as independent factors. Safety analysis showed comparable chemotherapy-related adverse events, except for a higher occurrence of ALT elevation in the HAI group.</p><p><strong>Conclusions: </strong>While our study showed no significant difference in three-year RFS, adjuvant chemotherapy intensification with HAI-FUDR is feasible and may offer early benefits in RFS and long-term OS. Nonetheless, a larger sample size is needed for validation and identifying which patient subgroup might benefit from this regimen.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT03500874.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"115154"},"PeriodicalIF":7.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.","authors":"Patrick Neven, Sileny Han, Didier Verhoeven, Adelheid Soubry","doi":"10.1016/j.ejca.2024.115166","DOIUrl":"https://doi.org/10.1016/j.ejca.2024.115166","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":" ","pages":"115166"},"PeriodicalIF":7.6,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.","authors":"Teresa Amaral, Lena Nanz, Lina Maria Serna Higuita, Paolo Ascierto, Carola Berking, Eva Muñoz Couselo, Marco Donia, Reinhard Dummer, Ralf Gutzmer, Axel Haushild, Mathilde Jalving, Rebecca Lee, Paul Lorigan, Ivan Marquez-Rodas, Olivier Michelin, Paul Nathan, Caroline Robert, Dirk Schadendorf, Pawel Sobczuk, Lukas Flatz, Ulrike Leiter, Claus Garbe","doi":"10.1016/j.ejca.2024.115160","DOIUrl":"https://doi.org/10.1016/j.ejca.2024.115160","url":null,"abstract":"<p><strong>Background: </strong>Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.</p><p><strong>Methods: </strong>We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software.</p><p><strong>Results: </strong>Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival.</p><p><strong>Conclusion: </strong>Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"215 ","pages":"115160"},"PeriodicalIF":7.6,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.","authors":"D Di Carlo, M Annereau, M Vignes, L Denis, N Epaillard, S Dumont, D Guyon, A Rieutord, S Jacobs, V Salomon, I Yoldjian, F Duperray, L Brunel, X Baiao, F Lemos, E Vauleon, M Capra, S Abbou, M Touat, M Sanson, V Gandemer, E De Carli, F Bourdeaut, I Hezam, G Vassal, J Grill","doi":"10.1016/j.ejca.2024.115165","DOIUrl":"https://doi.org/10.1016/j.ejca.2024.115165","url":null,"abstract":"<p><strong>Introduction: </strong>H3K27-altered diffuse midline gliomas (DMG) have limited therapeutic options and a very poor prognosis. Encouraging responses were observed in early clinical trials with ONC201. As ONC201 was unavailable in Europe, a compassionate use program supported by the French Authorities was launched for patients at progression after standard of care radiotherapy.</p><p><strong>Methods: </strong>This program was developed by the French Society of Pediatric Oncology (SFCE) and Association des Neuro-Oncologues d'Expression Française in collaboration with the French National Agency For Medicines and Health Products Safety and Parents Associations.</p><p><strong>Results: </strong>174 patients (102 children, 72 adults) from 14 countries were treated from November 2021 to August 2023 at Gustave Roussy Institut (Villejuif, France). 37 % received a second course of irradiation at the time of relapse. Median duration of treatment was 57 days or 1,9 months (mo) (range 1-456 days). Median OS since diagnosis for the whole cohort was 466 days or 15,5 mo (112-2612 days); 426 or 14,2 mo (112-2612 days) and 590 or 19,6 mo (range 160-1881) for children and adults, respectively (p = 0.001). Median OS after ONC201 start was 143 days or 4,7 mo (1-711 days) for the whole cohort. Univariate and multivariable analysis identified site (thalamus) and age (older) as favorable prognostic factors. Reirradiation was associated with significantly longer survival after ONC201 start only in children.</p><p><strong>Conclusion: </strong>While the efficacy of ONC201 needs validation in a controlled randomized clinical trial, our real-life data support a better outcome for patients with thalamic tumors treated with ONC201. We demonstrated furthermore the feasibility of a successful academia-driven compassionate use program.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"115165"},"PeriodicalIF":7.6,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.","authors":"Stanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, Susana Banerjee, Massimo Barberis, Robert L Coleman, Nicoletta Colombo, Anna DeFazio, Iain A McNeish, Angélica Nogueira-Rodrigues, Ana Oaknin, Sandro Pignata, Éric Pujade-Lauraine, Étienne Rouleau, Aleš Ryška, Nerina Van Der Merwe, Toon Van Gorp, Ignace Vergote, Wilko Weichert, Xiaohua Wu, Isabelle Ray-Coquard, Pascal Pujol","doi":"10.1016/j.ejca.2024.115169","DOIUrl":"https://doi.org/10.1016/j.ejca.2024.115169","url":null,"abstract":"<p><strong>Background: </strong>Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD. However, the optimal HRD testing strategy is an area of debate. Moreover, recently published clinical and translational data may impact how HRD status may be used to identify patients likely to benefit from PARPi use. We aimed to extensively compare available HRD CDx and establish a worldwide expert consensus on HRD testing in primary and recurrent OC.</p><p><strong>Methods: </strong>A group of 99 global experts from 31 different countries was formed. Using a modified Delphi process, the experts aimed to establish consensus statements based on a systematic literature search and CDx information sought from investigators, companies and/or publications.</p><p><strong>Results: </strong>Technical information, including analytical and clinical validation, were obtained from 14 of 15 available HRD CDx (7 academic; 7 commercial). Consensus was reached on 36 statements encompassing the following topics: 1) the predictive impact of HRD status on PARPi use in primary and recurrent OC; 2) analytical and clinical validation requirements of HRD CDx; 3) resource-stratified HRD testing; and 4) how future CDx may include additional approaches to help address unmet testing needs.</p><p><strong>Conclusion: </strong>This manuscript provides detailed information on currently available HRD CDx and up-to-date guidance from global experts on HRD testing in patients with primary and recurrent OC.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"215 ","pages":"115169"},"PeriodicalIF":7.6,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}